Management transitioned the company from a technology developer to a commercially driven 'gene editing engine' integrated into customer breeding programs. The value proposition has shifted to 'time-bound, predictable' trait development, returning edited elite germplasm to customers within 12 to 15 months. Performance in the rice (RISE) program is driven by seven customers representing a potential $200 million annual royalty opportunity across the Americas. The commercial model is evolving beyond sin ...